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 Objective To	provide	a synopsis	of	current	haemophilia	care	in	Hong	Kong.
 Design Retrospective	survey.
 Setting All	haematology	units	of	the	Hospital	Authority	in	Hong	Kong.
 Patients All	patients	with	haemophilia	A	and	haemophilia	B.	
 Results To	 date,	 there	 were	 222	 mild-to-severe	 haemophilia	 patients	
(192	type	A,	30	type	B)	under	regular	public	care	in	Hong	Kong	
(43%	were	 considered	 severe,	 33%	moderate,	 and	 24%	mild),	
which	gave	a	crude	prevalence	of	6.8/100	000	male	inhabitants.	
A	total	of	12.8	million	units	of	Factor	VIII	and	3	million	units	of	
Factor	IX	were	prescribed	annually.	This	amounts	to	1.83	units	of	
FVIII	per	capita	of	the	population,	which	is	comparable	to	that	
of	other	developed	countries.	Leading	causes	of	mortality	were	
human	immunodeficiency	virus–related	complications	(10	cases)	
and	cerebral	bleeding	(2	cases).	The	life	expectancy	of	patients	
with	 severe	 haemophilia	 in	Hong	Kong	 is	 improving;	 currently	
the	oldest	patient	 is	 60	 years	old.	 Such	 improved	 survival	may	
be	 due	 to	 enhanced	 factor	 availability,	 prompt	 treatment	 of	
bleeding	 episodes	 at	 home,	 safer	 factor	 products,	 and	 better	
antiviral	treatment.	Primary	prophylaxis	is	the	accepted	standard	
of	 care	 for	 severe	 and	moderate	 cases,	 and	 “Factor	 First”	 has	
become	 hospital	 policy.	 However,	 12	 patients	 continue	 to	
present	treatment	challenges,	due	to	the	documented	presence	
of	factor	inhibitors.	In	all,	28,	100,	and	14	cases	respectively	were	
positive	for	human	immunodeficiency	virus,	hepatitis	C	virus,	and	
hepatitis	B	virus;	 the	youngest	patients	with	 the	corresponding	
infections	being	28,	13,	and	22	years	old.	Comprehensive	care	with	
dedicated	physiotherapy,	 surgical	 support,	and	radionucleotide	
synovectomy	may	reduce	morbidity	further.	
 Conclusion A	multidisciplinary	approach	can	further	improve	the	future	care	
for	haemophilia	patients	in	Hong	Kong.
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Introduction
Hereditary haemophilia is a form of congenital bleeding tendency caused by deficiency of 
coagulation factors. Haemophilia A and B, caused by deficiency in coagulation factor (F) 
VIII and IX, are X-linked recessive conditions. There are currently 222 patients with mild-
to-severe haemophilia (all male) in Hong Kong under the care of the Hospital Authority. 
This is the closest to a regional registry1 and gives a crude prevalence of 6.8/100 000 male 
inhabitants. This is similar to rates in China and worldwide, which range from 6.6 ± 4.8 to 
12.8 ± 6, the variations are mainly due to the recognition of mild cases.2,3 In this article, 
we update the comprehensive care available to these patients.4 Patients with acquired 
haemophilia due to autoimmune antibodies,5 rare factor deficiencies (including FV/VIII 
combined deficiency),6-8 and von Willebrand disease9 are not covered in this review.
Demography
In all seven clusters of the Hospital Authority, patients with haemophilia are cared 
for by either adult or paediatric units according to age.4 The ratio of haemophilia A to 
haemophilia B patients is 6.4 to 1. Disease severity is classified according to clotting factor 
activity into severe (<1 IU/dL), moderate (1-5 IU/dL), and mild (>5-40 IU/dL). In our cohort, 
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Factor replacement
Both FVIII and FIX concentrates are available as 
specialist items under Hong Kong’s public health care 
at no additional cost to patients. Before 1992, both 
imported plasma products and non-virally inactivated 
local plasma products (eg fresh frozen plasma or 
cryoprecipitate) had been used for haemophilia 
treatment. Since 1992, high-purity FVIII and FIX 
concentrates became available from CSL (Australia) 
using Hong Kong donor plasma. Factor concentrate 
is the only recommended form of factor replacement 
for most haemophiliacs. The local blood has very low 
intrinsic risk for viral contamination. Multiple viral 
inactivation steps further reduce the estimated risks 
of hepatitis B virus (HBV), HCV, and HIV infection, by 
12.6, 9.8, and 20 logs respectively.11 At $450 per vial, 
the cost of FVIII (250 units) and FIX (500 units) vials 
for haemophilia patients remain a top budget item. 
In the year 2009, a total of 12 804 750 units of FVIII and 
3 049 000 units of FIX were prescribed. This translates 
to population factor use of 1.83 units of FVIII per 
capita, which is within affluent country standards 
(1.1-2.8 units per capita), and almost identical to factor 
consumption levels in Korea, Japan, and Singapore.12 
Recombinant products are only available as a patient-
paid item, and are only used by a small minority of 
young patients. Their local costs are 5-to-10–fold 
those of plasma products, but the relative risks of 
HBV, HCV, and HIV from recombinant products are 
negligible. 
 Prophylactic factor infusion (2-3 times per week, 
weight-adjusted from childhood) is now the standard 
of care in many countries.13 This policy prevents joint 
damage and allows normal lives for haemophiliacs. In 
the long run, it saves factor consumption and money 
by preventing bleeding complications and surgery 
due to long-term substandard care.14 There is also 
productivity gain from normal joints, and an improved 
lifestyle and lifespan.15,16 For very young kids, venous 
access may make starting prophylaxis difficult. For 
some patients with very difficult venous access, 
central venous catheters were inserted temporarily. 
Early fears of increased risks due to the development 
of inhibitors were mostly unsubstantiated. A survey 
of local patients showed that 57 local patients (34% 
of all severe-to-moderate cases, aged 2 to 36 years) 
are receiving prophylactic treatment. The remainder 
receive on-demand therapy. 
Inhibitors
The prevalence of inhibitors in Chinese haemophilia 
patients has been reported to be comparable to 
average rates worldwide.17 In these patients the 
treatment of bleeding is problematic, since they may 
be refractory even to high-dose factor replacement, 
which might also trigger a rebound in inhibitor 
 目的 提供香港血友病治療概覽。
 設計 回顧性問卷調查和年度資料更新。
 安排 香港醫院管理局轄下醫院的血液學部門。
 患者 所有甲型和乙型血友病患者。	
 結果 直至2011年1月為止，共222名（甲型192名、乙型
30名）輕微至嚴重血友病患者於公立醫療機構接受常
規治療；其中43%屬嚴重、33%屬中等、24%屬輕微
病例），而總現患率為每100 000男性居民有6.8人。
據統計，醫院每年為患者注射共1280萬個單位的第
八凝血因子，以及300萬個單位的第九凝血因子。換
言之，第八凝血因子的人均注射量為1.83個單位，數
字與其他已發展國家相若。患血友病的主因包括與愛
滋病毒相關的併發症（10宗病例）和腦出血（2宗病
例）。近年香港嚴重血友病患者的壽命有所改善，最
長的是60歲。這或與凝血因子供應量上升、患者在家
出現腦出血時能作即時治療、凝血因子產品較以往安
全，以及較佳的抗毒治療有關。初步的預防性因子注
射是中等至嚴重病例的可接受治療標準，而以凝血因
子作優先治療選擇也是現時醫院的治療政策。對愛滋
病毒、丙型肝炎病毒和乙型肝炎病毒呈陽性反應的病
例依次有28宗、100宗和14宗；而受上述病毒感染的
最年輕患者分別為28歲、13歲和22歲。然而，12名
患者在治療過程中出現因子抑制物，因此血友病治療
仍為醫務人員帶來挑戰。特定物理治療、外科治療和
放射性核素滑膜切除術的合作，有助進一步減低患病
率。
 結論 跨部門合作有助進一步改善對香港血友病患者的治
療。
香港血友病治療的現況概覽
the corresponding ratio of cases was 43%, 33% and 
24% (Fig a). Most patients were aged from 1 to 55 
years; with 27% aged younger than 18 years. Several 
factors affect the case prevalence (Fig b). Genetic 
counselling and prenatal diagnosis can prevent 
some severe familial cases, but de-novo mutations 
also occur. The prevalence of severe haemophilia in 
persons aged 0 to 30 years has actually been stable 
at 4-6/100 000 male inhabitants. Premature death in 
severe cases (due to bleeding and transfusion-related 
viral infections) leads to falling prevalence with 
increasing age. However, with more adequate factor 
usage, improved viral safety of factors and better 
treatment of human immunodeficiency virus (HIV)10 
and hepatitis C virus (HCV) infections, younger 
patients with severe (and moderate) haemophilia 
may have normal life expectancy. Mild-to-moderate 
cases may be diagnosed later in life. Our youngest 
mild case is now aged 5 years, and the prevalence of 
mild haemophilia shows no apparent variation with 
age. 
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titre due to an anamnestic response. Despite their 
very high costs, both bypass agents (Factor Eight 
Inhibitor Bypass Activity and recombinant activated 
Factor seven [Novoseven])18 are freely available for 
treating these patients. There were 12 such patients 
with inhibitors in Hong Kong, one of whom has 
haemophilia B. Their factor deficiency was severe in 
eight patients, moderate in three and mild in one, 
and their peak inhibitor levels ranged from 3 to 116 
Bethesda Units. The cumulative proportion of patients 
with severe-to-moderate deficiency with inhibitors 
was 8.5%. The reported cumulative figure in western 
countries varied from 7.5 to 30%, depending on 
frequency of testing and cohort inclusion criteria.13,19 
Notably, inhibitors were not detected in the cohort 
of local Hong Kong patients on regular prophylaxis. 
The experience with immune tolerance treatment is 
very limited. In three patients, low-dose regimens 
with steroids have been tried, one of whom achieved 
eradication of antibodies to FVIII.
Musculoskeletal damage
Prevention and treatment of musculoskeletal 
damage is the cornerstone for haemophilia care.20 
The prevalence, extent, and severity of joint 
damage in local haemophilia patients are not well 
documented. This is due to insufficient patient and 
FIG. (a) No. of patients and (b) case prevalence of patients in different age-groups by disease severity
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doctor enthusiasm and a shortage of dedicated 
physiotherapists and radiologists. In 2010, a regional 
specialist physiotherapy programme was launched 
in all clusters, in line with the China National 
Comprehensive Care Project in haemophilia.2 A 
comprehensive joint assessment score for both 
paediatric and adult patients was adopted, both 
in Hong Kong and in mainland China.21 Regular 
exercise (after appropriate factor replacement) is 
also important, with a view to prevent osteoporosis 
and fractures later in life.22 Joint assessments and 
scoring by plain X-rays, ultrasonography, computed 
tomography, and magnetic resonance imaging are 
also emerging in Hong Kong and China.23,24 
 The earliest joint damage in haemophilia is 
in the soft tissue, for which prevention is better 
than cure. By the time bone changes are evident, 
care is already suboptimal and the damage may 
already be irreversible. However, surgery, local 
radionucleotides and secondary prophylaxis can halt 
further damage and provide functional restoration.25 
All operative options (osteotomy, fusion, joint 
replacement) are available in three tertiary centres 
(Queen Mary Hospital, Prince of Wales Hospital, 
and Queen Elizabeth Hospital). With adequate use 
of factors, surgical risks are acceptable in Chinese 
haemophilia patients.26,27 There is no local registry 
of the total number and types of joints replaced. 
Radionucleotide synovectomy (Yttrium/Rhenium) is 
a new standard of care for progressive arthropathy,28 
particularly in conjunction with secondary factor 
prophylaxis.13,29 Expertise is available in three tertiary 
centres, but so far only 10 patients (9 haemophilia A 
cases and 1 haemophilia B case with inhibitor) have 
been treated with Yttrium in Hong Kong. All had knee 
injections, except for one who received bilateral 
ankle treatment.
Infections
The epidemic of HIV infection due to tainted 
imported factor products remained a dark chapter 
in the history of haemophilia care worldwide.30 
In Hong Kong, a total of 10 patients died of HIV-
related complications; while 28 are alive on antiviral 
therapy. These included mainly older patients (age 
28-52 years), and except for one FIX-deficient case, 
all had haemophilia A. Anti-retroviral treatment 
and the management of HIV-related infections and 
complications are under the care of the Department 
of Health, separate from haemophilia care. With 
optimal antiviral combination therapy, the CD4 
counts in most patients are at normal levels and their 
prognosis has improved vastly.31 
 The prevalence of HCV infection is even 
higher. The local prevalence of HCV carriage in 
blood donors is only 0.01%, but HCV antibody 
screening of blood products only started in 1993. 
Hence, previous use of imported factor products 
and local plasma products resulted in a high HCV 
antibody prevalence of 45% (100 cases; age range, 
13 to 79; median age, 38 years). The distribution of 
serotypes follows local prevalence.32 Treatment with 
a combination of pegylated interferon and ribavirin 
yields clearance rate from 53 to 67%,33,34 depending on 
the viral load and serotype. Up to 25% may have viral 
recrudescence, and lifelong follow-up for viraemia, 
hepatitis and hepatic tumour seems prudent. The 
use of fibroscan may help assess liver damage, since 
biopsy is not without risks in haemophiliacs.35 The 
carriage rate of HBV (6.5%, 14 cases; age range, 22-62; 
median age, 40 years) was not different from that in 
other age-matched locals. In Hong Kong, universal 
HBV vaccination of newborns began in 1988, and it is 
doubtful whether any older carriers are transfusion-
related. Interestingly, two local patients with HCV-
related non-resectable hepatocellular carcinoma 
(HCC) received living donor liver grafts and were 
cured of both HCC and haemophilia. Better control 
of HIV viral load also slowed the activity of the nearly 
inevitable concomitant HCV infection.36
Mortality
A total of 12 haemophilia patients have died in Hong 
Kong in the past 18 years. Except two patients with 
cerebral haemorrhage, all of them were HIV positive. 
Fulminant sepsis was the cause of death in nine of 
the cases, and HCV-related cirrhosis contributed to 
two other HIV deaths.36 The same pattern is seen in 
developed economies; where HIV-related deaths 
and end-stage liver diseases are the overwhelming 
causes of death.37,38 Up to 50% of patients were 
certified dead before reaching the medical ward 
and hospital proper. One HIV-negative patient died 
from intracranial haemorrhage in Mainland China. 
Education and training of patients and family members 
on early and appropriate home therapy is the most 
important first-line defense against morbidity and 
mortality. The availability of factors in the accident 
and emergency department, and the issuance of a 
“Factor First” policy at initial triage screening appears 
to reduce the pain, damage, bleeding, and possibly 
mortality of haemophilia patients coming to hospital 
for help. 
Social challenges 
The bleeding risks, frequent fixed contractures, and 
damaged joints prevent many haemophilia patients 
from undertaking vigorous exercise and other 
challenging activities. Parental fear may transfer to 
haemophiliac children, leading to harmful protective 
behaviour and social seclusion.39 Actually, light 
exercise should be encouraged and muscles around 
damaged joints must be strengthened. Moreover, 
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with appropriate factor replacement, a patient with 
haemophilia is no different from any other normal 
person. For patients adhering to prophylactic 
treatment, their joints can be completely normal. 
Haemophilia patients are therefore encouraged to 
take up normal lives and careers and families should 
avoid overprotecting their haemophiliac children.40 
The Patient Association (www.haemophilia.org.hk) 
serves to voice views and safeguard their well-being. 
Improved prognosis means that patients can have 
a normal life expectancy. There is a major role for 
parents, families, and caregivers in helping to move 
haemophilia patients from paediatric to adult care 
(and to geriatric care in due time).41,42 Since care 
models for paediatrics are not the same as in the 
adult set-up, uncoordinated transition can produce 
unnecessary anxiety and suffering for patients, 
families, and even caregivers. Such transfer is 
relevant, however, since adult medical complications 
may be better screened and managed by adult 
medicine physicians. The transition of care to an adult 
unit also facilitates the psychological progression for 
independent self-care. From a family perspective, 
patient families are also urged to take part in prenatal 
diagnosis and screening whenever there is a risk of 
passing the haemophilia gene to offspring. Genetic 
screening for carrier status should be extended to 
close female relatives, before they become pregnant. 
In one study in Southern Chinese, up to 35% of 
the molecular defects are unknown; hence linkage 
analysis on amniocentesis or chorionic villi sampling 
will be needed for some local families.43 
Conclusions
The future of haemophilia care in Hong Kong is bright. 
There are many unmet needs however, especially with 
increasing age and patient life expectancy. Emerging 
problems in adult haemophilia patients (renal failure, 
osteoporosis, cardiovascular morbidity) noted in 
other developed countries are also likely to surface 
in Hong Kong. There is also much need to improve 
genetic counselling, physiotherapy, and patient/
family education. Experience from Europe and 
America indicates that dedicated multidisciplinary 
haemophilia units—with better coordination between 
specialists in haematology, laboratory medicine, 
physiotherapy, orthopaedic surgery, nursing, medical 
social service and dentistry—improves patient care 
and satisfaction.44-46 Locally, in each of the seven 
clusters within Hong Kong, dedicated personnel 
are being identified and a critical mass of expertise 
is being established. Dialogue between the patient 
population and caregivers is also continuously 
improving. Such a multidisciplinary approach can 
improve the care of haemophilia patients and their 
families in Hong Kong.
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